Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas

Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas

The purpose of this research is to evaluate the diagnostic role and clinical efficacy of investigational FET-PET/MRI in detecting MRI-occult primary or residual/recurrent functional pituitary adenomas (PAs) and its influence on clinical and surgical decisions.

Inclusion Criteria:

• Patients 18 to 75 years of age with biochemically proven CD, Acromegaly, or tumor hyperprolactinemia as per current Endocrinology guidelines.
• Clinical DCE-MRI protocol that is negative or equivocal for identifiable tumor.
• Patient willing to have surgery if lesion found, or already scheduled for surgery and lesion identification would be helpful.
• Able to provide informed consent and be capable of completing the imaging protocols.
• Female subjects of childbearing potential (women of childbearing potential [WOCBP]) must have a negative urine pregnancy test ≤48 hours prior to the 18F-FET injection.

Exclusion Criteria:

• Patients with contraindications to MRI or PET scans.
• Patients with known allergies to contrast agents or other imaging-related materials.
• Patients with severe medical conditions that preclude participation in the study (e.g. inability to lie supine for 30-60 minutes).
• Patients with successful MRI localization of the adenoma.